Publications by authors named "Brian Kovacevich"
Article Synopsis
- ALD403 is a monoclonal antibody designed to inhibit CGRP, showing potential as a migraine preventive treatment with a good safety profile.
- The drug was developed by modifying rabbit antibodies to prevent unwanted immune reactions, and it effectively blocks CGRP-induced actions in lab tests.
- ALD403 did not trigger immune cell destruction mechanisms and demonstrated strong efficacy in animal studies by reducing blood flow response linked to pain, highlighting its potential for migraine management.
The multifunctional neuropeptide calcitonin gene-related peptide (CGRP) and its receptor are expressed throughout the gastrointestinal tract. Previous studies have shown that CGRP has roles in intestinal motility, water secretion, and inflammation. Furthermore, animal studies have demonstrated CGRP involvement in diarrhea secondary to C.
View Article and Find Full Text PDFThere is an unmet medical need for anabolic treatments to restore lost bone. Human genetic bone disorders provide insight into bone regulatory processes. Sclerosteosis is a disease typified by high bone mass due to the loss of SOST expression.
View Article and Find Full Text PDF